ArticleArchives of microbiology2025
A BCG-boosting subunit vaccine RS2/DMI induces Th1-polarized immunity by targeting RD6 and secretory antigens of Mycobacterium tuberculosis.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bacillus Calmette-Guérin (BCG) vaccine has limited protection against tuberculosis (TB) in adults, and there is an urgent need to develop novel TB vaccines. Currently, booster vaccines based on initial immunization with BCG are important research hotspots. In this study, we constructed recombinant protein RS2 by innovatively fusing Mycobacterium tuberculosis (M. tb) region of difference (RD) antigen Rv1506c with secretory phase antigen Rv3204, and developed a novel composite adjuvant DMI (dimethyl dioctadecylammonium bromide [DDA] + colloidal manganese salt [Mn jelly, MnJ] + imiquimod) to prepare a novel TB subunit vaccine, RS2/DMI. Population experiments showed that RS2 efficiently activated Th1-type cytokine secretion (IFN-γ/TNF-α/IL-2) in infected (active/ latent) individuals; in a mouse model, RS2/DMI as a BCG booster vaccine induced the highest level of IgG antibody response and the strongest Th1-polarized immune response - including the highest levels of Th1-type cytokines (IFN-γ/TNF-α /IL-2) and IFN-γ⁺IL-2⁺ double-positive CD4⁺/CD8⁺ T-cell production, and significantly better immunogenicity than the other adjuvant combinations (RS2/DMV, RS2/DIV) and BCG-immunized groups (P < 0.01). This immunological strategy also demonstrated matched preventive efficacy in ex vivo challenge experiment, confirming its potential as an efficient BCG booster vaccine and providing a new strategy to overcome the bottleneck of TB protection in adults.
Indexed as
Identifiers
41051521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.